Detalles de la búsqueda
1.
Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial.
Am Heart J;
237: 54-61, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33722585
2.
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial.
BMC Infect Dis;
19(1): 308, 2019 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30947693
3.
High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults.
Influenza Other Respir Viruses;
18(4): e13270, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38569647
4.
Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years.
Hum Vaccin Immunother;
18(6): 2106749, 2022 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35914122
5.
Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
Hum Vaccin Immunother;
17(12): 5475-5486, 2021 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34714720
6.
Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
Hum Vaccin;
6(10): 823-8, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20935517
7.
Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial.
Hum Vaccin Immunother;
16(6): 1380-1384, 2020 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31810418
8.
Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35â¯months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres.
Vaccine;
37(13): 1885-1888, 2019 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745147
9.
Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35â¯months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Vaccine;
37(13): 1876-1884, 2019 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30558818
10.
Corrigendum to "Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres" [Vaccine 37(13) (2019) 1885-1888].
Vaccine;
41(2): 621, 2023 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36509639
11.
Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Hum Vaccin Immunother;
14(3): 596-608, 2018 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28968138
12.
Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
Expert Rev Vaccines;
17(1): 1-11, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29157068
13.
Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.
PLoS One;
11(11): e0165384, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27814377
14.
Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Hum Vaccin Immunother;
12(12): 3072-3078, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27565435
15.
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Vaccine;
33(21): 2485-92, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25843270
16.
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Vaccine;
31(47): 5572-8, 2013 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24016810
17.
Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age.
Hum Vaccin Immunother;
8(9): 1283-92, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22906943
18.
Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin.
PLoS One;
4(11): e7918, 2009 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19936250
19.
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
Vaccine;
27(49): 6918-25, 2009 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19761837
20.
Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children.
PLoS One;
3(12): e4028, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19112513